Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax (2012 - 2026)

Catalyst Pharmaceuticals' Long-Term Deferred Tax history runs 11 years deep, the most recent figure standing at $55.1 million for Q1 2026.

• Quarterly Long-Term Deferred Tax rose 14.29% year-over-year to $55.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.1 million (up 14.29% YoY) and the FY2025 annual result came in at $52.8 million, up 14.76% from the prior year.
• Long-Term Deferred Tax was $55.1 million for Q1 2026 at Catalyst Pharmaceuticals, up from $52.8 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $55.1 million in Q1 2026 and bottomed at $18.7 million in Q4 2022.
• A 5-year average of $36.9 million and a median of $38.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax tumbled 30.33% — and 2023, when it jumped 95.05%.
• Catalyst Pharmaceuticals' Long-Term Deferred Tax stood at $18.7 million in 2022, then soared by 95.05% to $36.5 million in 2023, then climbed by 25.83% to $46.0 million in 2024, then grew by 14.76% to $52.8 million in 2025, then advanced by 4.44% to $55.1 million in 2026.
• Business Quant data shows CPRX's Long-Term Deferred Tax at $55.1 million in Q1 2026, $52.8 million in Q4 2025, and $48.3 million in Q3 2025.